Biotechs can explode - Watch Resverlogix......
Post# of 98056
This could be massive, Chinese Pharmaceutical Shenzhen Hepalink is waiting regulatory approval of an $87 million investment in Canadian Biotech Resverlogix, a company engaged in the the development of Apabetalone a Selective BET Inhibitor.
Apabetalone is in a Phase III trial. Read more here:
http://www.avoidthebag.com/2017/11/bet-inhibi...ng-in.html
RVX.TO on Canada's main TSX or $RVXCF in the US.